Search results
Results from the WOW.Com Content Network
(Reuters) -Edwards Lifesciences Corp on Wednesday reported a rise in third-quarter sales, but lower-than-expected sales of the company's artificial heart valves pushed the device maker's shares ...
Edwards Lifesciences (EW) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Edwards Lifesciences shares fall as slow heart-valve growth dulls forecast raise. ... In the quarter ended June 30, Edwards' revenue rose 11% to $1.53 billion, above estimates of $1.50 billion.
Edwards Lifesciences is an American medical technology company headquartered in Irvine, California, specializing in artificial heart valves and hemodynamic monitoring. It developed the SAPIEN transcatheter aortic heart valve made of cow tissue within a balloon-expandable, cobalt-chromium frame, deployed via catheter . [ 4 ]
Edwards Lifesciences (EW) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Investors continue to be optimistic about Edwards Lifesciences' (EW) performance. For premium support please call: 800-290-4726 more ways to reach us
PRINCETON, N.J., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, today reported financial results for the third quarter ending September 30, 2024. Third Quarter 2024 Highlights. Third quarter revenues of $380.8 million decreased 0.4% on a reported basis and ...
Third quarter financial results. Revenue for the third quarter ended October 31, 2024 was $300.4 million, an increase of 21% compared to $249.2 million for the third quarter ended October 31, 2023. Revenue this quarter included: service revenue of $119.2 million, custodial revenue of $141.0 million, and interchange revenue of $40.3 million.